MORAGA, CA, USA I August 29, 2013 I Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, announced that David C. Yeomans, Ph.D., Chief Scientist and Founder of Trigemina, as well as the Director of Pain Research at Stanford University School of Medicine, presented at the 2013 Napa Pain Conference on August 23rd — 25th, 2013 in Napa, California.
The presentation, titled, “Direct Drug Delivery of Oxytocin for Treatment of Trigeminal Neuralgia,” occurred on Friday, August 23rd, from 11:50 AM to 12:25 PM PT. Dr. Yeomans provided data and insight from preclinical studies with TI-001, an intranasal oxytocin therapeutic, and its potential therapeutic value in the treatment of trigeminal neuralgia, a severe nerve disorder commonly known as the suicide disease due to sufferers experiencing episodes of intense and debilitating facial pain.
“Leading pain clinicians and scientists from around the world were fascinated with the study and several expressed interest in getting involved,” said Dr. Yeomans. “The idea that a painful neurological condition, such as trigeminal neuralgia or chronic migraine, can be treated with oxytocin catches many by surprise. Most researchers look outside the body, but this study shows that our very own body already has a way to manage chronic head pain, it just needs a little boost from therapeutics like TI-001.”
TI-001, which is the Company’s leading drug candidate, is currently being evaluated in a placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched Phase II clinical study, titled TRIG-05, for efficacy, tolerability and safety in patients with chronic migraine. Promising preclinical and human pilot study results suggests TI-001 could be a safe, non-narcotic form of therapy for the effective relief of chronic migraine, a debilitating condition with few treatment options.
About Trigemina
Trigemina is focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina’s lead product candidate, TI-001, is a patented new application of oxytocin. TI-001 has shown promising results for use as a safe and effective therapy for all forms of chronic and subacute head pain.
SOURCE: Trigemina
Post Views: 181
MORAGA, CA, USA I August 29, 2013 I Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, announced that David C. Yeomans, Ph.D., Chief Scientist and Founder of Trigemina, as well as the Director of Pain Research at Stanford University School of Medicine, presented at the 2013 Napa Pain Conference on August 23rd — 25th, 2013 in Napa, California.
The presentation, titled, “Direct Drug Delivery of Oxytocin for Treatment of Trigeminal Neuralgia,” occurred on Friday, August 23rd, from 11:50 AM to 12:25 PM PT. Dr. Yeomans provided data and insight from preclinical studies with TI-001, an intranasal oxytocin therapeutic, and its potential therapeutic value in the treatment of trigeminal neuralgia, a severe nerve disorder commonly known as the suicide disease due to sufferers experiencing episodes of intense and debilitating facial pain.
“Leading pain clinicians and scientists from around the world were fascinated with the study and several expressed interest in getting involved,” said Dr. Yeomans. “The idea that a painful neurological condition, such as trigeminal neuralgia or chronic migraine, can be treated with oxytocin catches many by surprise. Most researchers look outside the body, but this study shows that our very own body already has a way to manage chronic head pain, it just needs a little boost from therapeutics like TI-001.”
TI-001, which is the Company’s leading drug candidate, is currently being evaluated in a placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched Phase II clinical study, titled TRIG-05, for efficacy, tolerability and safety in patients with chronic migraine. Promising preclinical and human pilot study results suggests TI-001 could be a safe, non-narcotic form of therapy for the effective relief of chronic migraine, a debilitating condition with few treatment options.
About Trigemina
Trigemina is focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina’s lead product candidate, TI-001, is a patented new application of oxytocin. TI-001 has shown promising results for use as a safe and effective therapy for all forms of chronic and subacute head pain.
SOURCE: Trigemina
Post Views: 181
